Search results for "Benzyl"
showing 10 items of 878 documents
CCDC 1433602: Experimental Crystal Structure Determination
2017
Related Article: H. Purandara, S. Foro, B. Thimme Gowda|2017|Acta Crystallogr.,Sect.E:Cryst.Commun.|73|1683|doi:10.1107/S2056989017014669
CCDC 634267: Experimental Crystal Structure Determination
2007
Related Article: S.Dobis, D.Schollmeyer, Chunmei Gao, Derong Cao, H.Meier|2007|Eur.J.Org.Chem.|2007|2964|doi:10.1002/ejoc.200700140
CCDC 906031: Experimental Crystal Structure Determination
2013
Related Article: Pekka K.Poutiainen ,Jorma J.Palvimo,Ari E.Hinkkanen,Arto Valkonen,Topi K.Vaisanen,Reino Laatikainen,Juha T.Pulkkinen|2013|J.Med.Chem.|56|1064|doi:10.1021/jm301516q
CCDC 906030: Experimental Crystal Structure Determination
2013
Related Article: Pekka K.Poutiainen ,Jorma J.Palvimo,Ari E.Hinkkanen,Arto Valkonen,Topi K.Vaisanen,Reino Laatikainen,Juha T.Pulkkinen|2013|J.Med.Chem.|56|1064|doi:10.1021/jm301516q
CCDC 1913148: Experimental Crystal Structure Determination
2019
Related Article: Hongxin Chai, Zhi-Sheng Pan, Liu-Pan Yang, Shan He, Fangfang Pan, Kari Rissanen, Wei Jiang|2019|Chem.Commun.|55|7768|doi:10.1039/C9CC03341F
CCDC 1402129: Experimental Crystal Structure Determination
2016
Related Article: Carla Queirós, Andreia Leite, Maria G. M. Couto, mLuís Cunha-Silva, Giampaolo Barone, Baltazar de Castro, Maria Rangel, André M. N. Silva, Ana M. G. Silva|2015|Chem.-Eur.J.|21|15692|doi:10.1002/chem.201502093
N-SUBSTITUTION AND á1-ADRENERGIC RECEPTOR AFFINITY OF LAUDANOSINE ANALOGUES
2006
Benzyltetrahydroisoquinoline (BTHIQ) molecules are able to adopt widely differing conformations that depend on the presence or absence of N-substituents. To assess the possible role of BTHIQ conformation on the affinity of these compounds for α 1 -adrenergic receptors, of interest for the management of hypertension, the racemic N-unsubstituted BTHIQ norlaudanosine and a series of N-alkylated derivatives were assessed for binding to rat brain cortical sites labelled with the radioligand [3H]prazosin. The α 1 -adrenergic affinity in this series increased with the bulk of the substituent on the nitrogen atom, from the N-ethyl to the N-propyl analogue. Comparison of these results with published…
δ 1‐OPIOID receptor‐mediated controlofacetylcholine (ACh) release in human neocortex slices
1998
In slices of human neocortex, prelabelled with [3H]-choline, the release of [3H]-acetylcholine reflects the evoked release of endogenous acetylcholine which was elicited by the same electrical stimulation paradigm. [3H]-Acetylcholine release was depressed by the delta-opioid receptor agonist D-Pen2-D-Pen5-enkephalin. When the nerve endings were depolarized by elevating extracellular potassium the evoked [3H]-acetylcholine release was similarly depressed by D-Pen2-D-Pen5-enkephalin in the absence, but not in the presence, of tetrodotoxin which blocks action potential propagation. Therefore, the delta-opioid receptor inhibiting [3H]-acetylcholine release should not be located to cholinergic n…
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
2010
The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 …
Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study
2014
Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …